+120.4%
NXT vs GSK
+51.8%
+68.5%
-57.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -11.6% | -0.1% | -11.5% | -11.6% |
| 7D | -29.4% | -5.3% | -24.0% | -28.5% |
| 30D | -17.9% | -3.7% | -14.2% | -17.2% |
| 3M | -23.6% | -7.3% | -16.3% | -22.4% |
| 6M | -46.5% | -4.2% | -42.2% | -46.2% |
| YTD | -22.9% | +0.9% | -23.8% | -23.4% |
| 1Y | -21.8% | +7.3% | -29.1% | -23.4% |
| 3Y | +69.1% | +52.7% | +16.4% | +40.5% |
| All | +120.4% | +51.8% | +68.5% | +87.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling